Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

Recent Highlights from some of our Founders

Tim Newton (PhD, Medicine) worked on commercialisation of novel proof of concept therapeutics at Alzheimer's Research UK Cambridge Drug Discovery Institute before joining DSV to launch Reflection Therapeutics - developing targeted anti-inflammatory cell therapies to reduce neuroinflammation at key sites within a patients central nervous system.

Won Accelerate@Babraham 2019 including free access to state of the art laboratory space, built prototype receptors functioning in vitro and secured over £500k in non-dilutive funding from DSV, Innovate UK and MedCity.

Founder of Ancilia, Alexandra Sakatos (PhD, Microbiology), led research and product development at a New York based biotech prior to joining DSV. Ancilia are developing a new class of engineered bacterial therapies that effectively alter the human to treat the growing number of diseases linked to the microbiome, starting with IBD.

Generated bioinformatics platform for phage identification and demonstrated POC for phage culturing in vitro, established a research collaboration with Washington University in St. Louis and brought on Rodolphe Barrangou (discoverer of CRISPR) as a Co-Founder and SCO.

Nathan Payne (MSci, Geophysics) formed Optic Earth at DSV following an 8-year career with a major geophysical service provider in roles covering seismic imaging, sales, and marketing. Optic Earth are building advanced technologies to reduce the turnaround and quantify the uncertainty of subsurface imaging, allowing energy companies to have more confidence in their seismic data.

Raised over £300k pre-seed through public and private investment, including DSV and the OGTC, have won commercial projects with energy majors and are expanding their team rapidly.

Alexander Murdock (BASc, Chemical & Biological Engineering) worked for multinationals Air Liquide and Hatch before joining DSV to co-found Thermulon - deploying the latest advances in chemical and processing technology into a product that meets the construction industry’s needs in the face of increasing regulatory standards.

Partnered with global technology leaders in plaster formulations and insulation material integration, secured a £6m collaboration with the top European insulation panel producer and currently in late stage negotiations to undergo full-wall material/fire testing with global concrete specialists.

Tim Newton (PhD, Medicine) worked on commercialisation of novel proof of concept therapeutics at Alzheimer's Research UK Cambridge Drug Discovery Institute before joining DSV to launch Reflection Therapeutics - developing targeted anti-inflammatory cell therapies to reduce neuroinflammation at key sites within a patients central nervous system.

Won Accelerate@Babraham 2019 including free access to state of the art laboratory space, built prototype receptors functioning in vitro and secured over £500k in non-dilutive funding from DSV, Innovate UK and MedCity.

Founder of Ancilia, Alexandra Sakatos (PhD, Microbiology), led research and product development at a New York based biotech prior to joining DSV. Ancilia are developing a new class of engineered bacterial therapies that effectively alter the human to treat the growing number of diseases linked to the microbiome, starting with IBD.

Generated bioinformatics platform for phage identification and demonstrated POC for phage culturing in vitro, established a research collaboration with Washington University in St. Louis and brought on Rodolphe Barrangou (discoverer of CRISPR) as a Co-Founder and SCO.

Nathan Payne (MSci, Geophysics) formed Optic Earth at DSV following an 8-year career with a major geophysical service provider in roles covering seismic imaging, sales, and marketing. Optic Earth are building advanced technologies to reduce the turnaround and quantify the uncertainty of subsurface imaging, allowing energy companies to have more confidence in their seismic data.

Raised over £300k pre-seed through public and private investment, including DSV and the OGTC, have won commercial projects with energy majors and are expanding their team rapidly.

Alexander Murdock (BASc, Chemical & Biological Engineering) worked for multinationals Air Liquide and Hatch before joining DSV to co-found Thermulon - deploying the latest advances in chemical and processing technology into a product that meets the construction industry’s needs in the face of increasing regulatory standards.

Partnered with global technology leaders in plaster formulations and insulation material integration, secured a £6m collaboration with the top European insulation panel producer and currently in late stage negotiations to undergo full-wall material/fire testing with global concrete specialists.

Companies we’ve co-founded and invested in since 2017